Camber Pharmaceuticals Inc. 2023-05-17 Health critical FDA
Health · FDA · Recall #FDA-D-0567-2023
Atovaquone Oral Suspension USP, 750 mg/5 mL, Packaged in 210 mL bottle, Manufactured for:… Recall
Issued May 17, 2023 · Camber Pharmaceuticals Inc.
In May 2023, Camber Pharmaceuticals Inc. recalled the Atovaquone Oral Suspension USP, 750 mg/5 mL, Packaged in 210 mL bottle, Manufactured for:…, a critical health recall reported by the FDA. Affected owners are eligible for a voluntary. Here is what the hazard is and exactly what to do about it.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Microbial Contamination of Non-Sterile Product: Objectionable organism, identified as Bacillus cereus, found in product during testing of repackaged product.
What you should do
- 1 Stop using Atovaquone Oral Suspension USP, 750 mg/5 mL, Packaged in 210 mL bottle, Manufactured for:… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Camber Pharmaceuticals Inc. to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Camber Pharmaceuticals Inc.
- Category
- Health
- Recall date
- May 17, 2023
- Units affected
- Not reported
- Sold at
- Nationwide in the USA
- Recall number
- FDA-D-0567-2023
- Made in
- United States
- Issuing agency
- FDA
In context
- Camber Pharmaceuticals Inc. has 1 recall in our database, including 1 rated Critical.
- We're tracking 3,576 Health recalls in our database.
- This is the 903rd Health recall we've logged in 2023.